Show simple item record

dc.contributor.authorPereira, Renato B.
dc.contributor.authorEvdokimov, Nikolai M.
dc.contributor.authorLefranc, Florence
dc.contributor.authorValentao, Patricia
dc.contributor.authorKornienko, Alexander
dc.contributor.authorPereira, David M.
dc.contributor.authorAndrade, Paula B.
dc.contributor.authorGomes, Nelson G. M
dc.date.accessioned2019-07-30T14:41:55Z
dc.date.available2019-07-30T14:41:55Z
dc.date.issued2019
dc.identifier.citationPereira, R. B., Evdokimov, N. M., Lefranc, F., Valentão, P., Kornienko, A., Pereira, D. M., Andrade, P. B., & Gomes, N. G. M. (2019). Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets. Marine Drugs, 17(6), 329.en_US
dc.identifier.urihttps://digital.library.txstate.edu/handle/10877/8416
dc.description.abstractThe role of the marine environment in the development of anticancer drugs has been widely reviewed, particularly in recent years. However, the innovation in terms of clinical benefits has not been duly emphasized, although there are important breakthroughs associated with the use of marine-derived anticancer agents that have altered the current paradigm in chemotherapy. In addition, the discovery and development of marine drugs has been extremely rewarding with significant scientific gains, such as the discovery of new anticancer mechanisms of action as well as novel molecular targets. Approximately 50 years since the approval of cytarabine, the marine-derived anticancer pharmaceutical pipeline includes four approved drugs and eighteen agents in clinical trials, six of which are in late development. Thus, the dynamic pharmaceutical pipeline consisting of approved and developmental marine-derived anticancer agents offers new hopes and new tools in the treatment of patients afflicted with previously intractable types of cancer.en_US
dc.formatText
dc.format.extent21 pages
dc.format.medium1 file (.pdf)
dc.language.isoen_USen_US
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)en_US
dc.sourceMarine Drugs, 2019, Vol. 17, No. 6, 329
dc.subjectCytarabineen_US
dc.subjectTrabectedin
dc.subjectEribulin
dc.subjectBrentuximab vedotin
dc.subjectPlitidepsin
dc.subjectLurbinectedin
dc.subjectPlinabulin
dc.subjectMarizomib
dc.subjectPlocabulin
dc.subjectAntibody–drug conjugates
dc.titleMarine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targetsen_US
txstate.documenttypeArticle
dc.identifier.doihttps://doi.org/10.3390/md17060329
txstate.departmentChemistry and Biochemistry


Download

Thumbnail

This item appears in the following Collection(s)

Show simple item record